Heparin's anticoagulation effect makes it the principal component in the immediate treatment of all thrombotic diseases. After hemorrhage, the most important complication of heparin is thrombocytopenia, the decrease in the number of blood platelets. Ten cases of "heparin-induced thrombocytopenia" are described, and guidelines for diagnosing heparin-induced thrombocytopenia in patients who present for cardiac and vascular surgery are given. Methods of treating patients with heparin-induced thrombocytopenia, including use of arachidonic acid derivatives, antiplatelet agents, other anticoagulants, heparinoids, natural and synthetic thrombin inhibitors, hirudin, and defibrinogenation with ancrod, are discussed.
Get full access to this article
View all access options for this article.
References
1.
Fidlar E., Jaques L.: The effect of commercial heparin on the platelet count. J Lab Clin Med33:1410-1423, 1948
2.
Weissmann R. , Tobin R.: Arterial embolism occurring during systemic heparin therapy. Arch Surg76:219-227, 1958
3.
Warkentin TE : Heparin-induced thrombocytopenia: IgGmediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus Med Rev10:249-258, 1996
4.
Kelton JG, Sheridan D., Brain H., et al: Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med103:606-612, 1984
5.
Nelson JC, Lerner RG, Goldstein R., Cagin NA: Heparin-induced thrombocytopenia. Arch Intern Med138:548-552,1978
6.
King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med100:535-540, 1984
Warkentin TE , Levine MN, Hirsh J., et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin . N Engl J Med332:1330-1335, 1995
13.
Brace LD, Fareed J.: Heparin-induced platelet aggregation: Dose/response relationships for a low-molecular-weight heparin derivative (PK 10169) and its subfractions . Thromb Res42:769-782, 1986
14.
Killer S., Zoppi M., Kunzi UP, et al: [Heparin-induced thrombocytopenia. Results from the Comprehensive Hospital Drug Monitoring (CHDM)Bern/ St. Gallen]. Schweiz Med Wochenschr125:2518-2522, 1995
15.
Thunberg L. , Lindahl U., Tengblad A., et al: On the molecular-weight-dependence of the anticoagulant activity of heparin. Biochem J181:241-243, 1979
16.
Salzman EW, Rosenberg RD, Smith MH, et al: Effect of heparin and heparin fractions on platelet aggregation . J Clin Invest65:64-73, 1980
17.
Bell WR: Heparin-associated thrombocytopenia and thrombosis. J Lab Clin Med111:600-605, 1988
18.
Makhoul RG, Greenberg CS, McCann RL: Heparin-associated thrombocytopenia and thrombosis: A serious clinical problem and potential solution. J Vasc Surg4:522-528, 1986
19.
Krueger SK, Andres E., Weinand E.: Thrombolysis in heparin-induced thrombocytopenia with thrombosis. Ann Intern Med103:159, 1985 (letter)
20.
Atkinson JL , Sundt TMJr, Kazmier FJ, et al: Heparin-induced thrombocytopenia and thrombosis in ischemic stroke. Mayo Clin Proc63:353-361, 1988
21.
Dieck JA, Rizo Patron C, Unisa A., et al: A new manifestation and treatment alternative for heparin-induced thrombosis. Chest98:1524-1526, 1990
22.
Gupta BK, Savage MP, Brest AN: Acute myocardial infarction during coronary angioplasty associated with heparin-induced thrombocytopenia. Cathet Cardiovasc Diagn35:42-46, 1995
23.
Leroy J., Leclerc MH, Delahousse B., et al: Treatment of heparin-associated thrombocytopenia and thrombosis with low-molecular-weight heparin (CY 216). Semin Thromb Hemost11:326-329, 1985
24.
Ceriana P., Maurelli M., Locatelli A., et al: Pseudomyxoma of the right atrium in a patient with heparin-associated thrombocytopenia and antiphospholipid antibodies. J Cardiothorac Vasc Anesth9:308-311, 1995
25.
Elliott LD, Lichtenberg R., Johnson SA, Lewis BE: Diagnosis and management of right atrial thrombus in heparin-induced thrombocytopenia and thrombosis syndrome with transesophageal echocardiography and thrombolytic therapy. Am Heart J131:1227-1229, 1996
26.
Scheffold N. , Greinacher A., Cyran J.[Intracardial thrombus formation in heparin-associated thrombocytopenia type II] . Dtsch Med Wochenschr120:519-522, 1995
27.
Vignon P., Gueret P., Francois B., et al: Acute limb ischemia and heparin-induced thrombocytopenia: The value of echocardiography in eliminating a cardiac source of arterial emboli . J Am Soc Echocardiogr9:344-347,1996
28.
Auger WR, Permpikul P., Moser KMLupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: A preliminary report. Am J Med99:392-396, 1995
29.
Towne JB, Bernhard VM, Hussey C., Garancis JC: White clot syndrome. Peripheral vascular complications of heparin therapy . Arch Surg114:372-377, 1979
Walls JT, Curtis JJ, Silver D., et al: Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition. Ann Thorac Surg53:787-791, 1992
32.
Cummins D., Halil O., Amin S.: Which patients undergoing cardiopulmonary bypass should be assessed for development of heparin-induced thrombocytopenia?Thromb Haemost73:890, 1995 (letter)
33.
Lecrubier C. , Conard J., Horellou MH, et al: Spontaneous platelet aggregation in heparin-treated patients. Acta Haematol71:63-65, 1984
34.
Hach Wunderle V, Kainer K., Krug B., et al: Heparin-associated thrombosis despite normal platelet counts. Lancet344:469-470, 1994 (letter)
35.
Kappa JR, Fisher CA, Berkowitz HD, et al: Heparin-induced platelet activation in sixteen surgical patients: Diagnosis and management. J Vasc Surg5:101-109, 1987
36.
Warkentin TE , Kelton JG: Heparin and platelets. Hematol Oncol Clin North Am4:243-264, 1990
37.
Sobel M., McNeill PM, Carlson PL, et al: Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest87:1787-1793, 1991
38.
Heiden D., Mielke CHJr, Rodvien R.: Impairment by heparin of primary haemostasis and platelet [14C]5-hydroxytryptamine release. Br J Haematol36:427-436, 1977
39.
Reches A., Eldor A., Salomon Y.: Heparin inhibits PGE1-sensitive adenylate cyclase and antagonizes PGE1 antiaggregating effect in human platelets. J Lab Clin Med93:638-644, 1979
40.
Greilich PE , Carr ME Jr, Carr SL, Chang AS: Reductions in platelet force development by cardiopulmonary bypass are associated with hemorrhage . Anesth Analg80:459-465, 1995
41.
Reininger CB , Greinacher A., Graf J., et al: Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res81:641-649, 1996
42.
Elalamy I., Lecrubier C., Potevin F., et al: Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost74:1384-1385, 1995 (letter)
43.
Visentin GP , Malik M., Cyganiak KA, Aster RH: Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J Lab Clin Med128:376-383,1996 (comments)
44.
Adelman B., Sobel M., Fujimura Y., et al: Heparin-associated thrombocytopenia: Observations on the mechanism of platelet aggregation. J Lab Clin Med113:204-210, 1989
45.
Stricker RB , Reyes PT, Corash L., Shuman MA: Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor . J Clin Invest79:1589-1594, 1987
46.
Kelton JG, Smith JW, Warkentin TE, et al: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood83:3232-3239, 1994
47.
Amiral J., Bridey F., Dreyfus M., et al: Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost1992;68:95-96, 1992 (letter, comments)
48.
Kelton JG, Powers PJ, Carter CJ: A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenia purpura. Blood60:1050-1053, 1982
49.
Luzzatto G. , Cordiano I., Patrassi G., Fabris F.: Heparin-induced thrombocytopenia: Discrepancy between the presence of IgG cross-reacting in vitro with fraxiparine and its successful clinical use. Thromb Haemost74:1607-1609, 1995
50.
Chong BH, Burgess J., Ismail F.: Th e clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost69:344-350, 1993
51.
Sheridan D. , Carter C., Kelton JG: A diagnostic test for heparin-induced thrombocytopenia . Blood67:27-30, 1986
52.
Magnani HN: Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172) [published erratum appears in Thromb Haemost70:1072, 1993]. Thromb Haemost70:554-561, 1993
53.
Amiral J., Bridey F., Wolf M., et al: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb Haemost73:21-28,1995
54.
Jackson M., Krishnamurti C., Aylesworth C., Alving B.: Diagnosis of heparin-induced thrombocytopenia in the vascular surgery patient . Surgery121:419-424, 1997
55.
Arepally G. , Reynolds C., Tomaski A., et al: Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia . Am J Clin Pathol104:648-654, 1995
56.
Green D., Harris K., Reynolds N., et al: Heparin-immune thrombocytopenia: Evidence for a heparin-platelet complex as the antigenic determinant. J Lab Clin Med91:167-175, 1978
57.
Kakkasseril JS , Cranley JJ, Panke T., Grannan K.: Heparin-induced thrombocytopenia: A prospective study of 142 patients. J Vasc Surg2:382-384, 1985
Kunisch M., Rauber K., Bachmann G., Rau WS: [Temporary cava filter: effective prophylaxis of pulmonary embolism in venous thrombosis in the region of the pelvic vascular system and the inferior vena cava?]Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr163: 523-526, 1995
60.
Kappa JR, Cottrell ED, Berkowitz HD, et al: Carotid endarterectomy in patients with heparin-induced platelet activation: Comparative efficacy of aspirin and Iloprost (ZK36374). J Vasc Surg5:693-701, 1987
61.
Sobel M., Adelman B., Szentpetery S., et al: Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J Vasc Surg8:395-401, 1988
62.
Cole CW, Fournier LM, Bormanis J.: Heparin-associated thrombocytopenia and thrombosis: Optimal therapy with ancrod . Can J Surg33:207-210, 1990
63.
Bichler J., Fritz H.: Hirudin, a new therapeutic tool?Ann Hematol63:67-76, 1991
64.
Cohen JI, Cooper MR, Greenberg CS: Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia . Arch Intern Med145:1725-1726, 1985
65.
Cummings JM , Mason TJ, Chomka EV, Pouget JM: Fibrinolytic therapy of acute myocardial infarction in the heparin thrombosis syndrome . Am Heart J112:407-409, 1986
66.
Weinmann EE , Carpenter JP: Intraoperative urokinase as an alternative to heparin for patients with suspected heparin-induced thrombocytopenia requiring arterial reconstruction: Report of a case and review of the literature . J Cardiovasc Surg Torino37:463-465, 1996
67.
Murphy KD, McCrohan G., DeMarta DA, et al: The heparin-induced thrombocytopenia and thrombosis syndrome: Treatment with intraarterial urokinase and systemic platelet aggregation inhibitors . Cardiovasc Intervent Radiol19:123-127, 1996
68.
Mehta DP, Yoder EL, Appel J., Bergsman KL: Heparin-induced thrombocytopenia and thrombosis: Reversal with streptokinase. A case report and review of literature. Am J Hematol36:275-279, 1991
69.
Vender JS, Matthew EB, Silverman IM, et al: Heparin-associated thrombocytopenia: Alternative managements . Anesth Analg65:520-522, 1986
70.
Ansell JE, Price JM, Shah S., Beckner RR: Heparin-induced thrombocytopenia. What is its real frequency?Chest88:878-882, 1985
71.
Laster J., Cikrit D., Walker N., Silver D.: The heparin-induced thrombocytopenia syndrome: An update. Surgery102:763-770, 1987
72.
Rhodes GR, Dixon RH, Silver D.: Heparin-induced thrombocytopenia: Eight cases with thrombotic-hemorrhagic complications. Ann Surg186:752-758, 1977
73.
Addonizio VP Jr, Fisher CA, Kappa JR, Ellison N.: Prevention of heparin-induced thrombocytopenia during open heart surgery with Iloprost (ZK36374) . Surgery102:796-807, 1987
74.
Kappa JR, Horn MK 3rd, Fisher CA, et al: Efficacy of Iloprost (ZK36374) versus aspirin in preventing heparin-induced platelet activation during cardiac operations. J Thorac Cardiovasc Surg94:405-413, 1987
75.
Shorten G., Comunale ME, Johnson RG: Management of cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia using prostaglandin E1 and aspirin. J Cardiothorac Vasc Anesth8:556-558, 1994
76.
Long RW: Management of patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass. J Thorac Cardiovasc Surg89:950-951, 1985 (letter)
77.
Smith JP, Walls JT, Muscato MS, et al: Extracorporeal circulation in a patient with heparin-induced thrombocytopenia. Anesthesiology62:363-365, 1985
78.
Makhoul RG, McCann RL, Austin EH, et al: Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. Ann Thorac Surg43:617-621, 1987
79.
Hirsh J.: Heparin. N Engl J Med324:1565-1574, 1991
80.
Bowler SD, Smith SM, Lavercombe PS: Heparin inhibits the immediate response to antigen in the skin and lungs of allergic subjects. Am Rev Respir Dis147:160-163, 1993
81.
Holmer E., Kurachi K., Soderstrom G.: The molecular-weight-dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J193:395-400, 1981
82.
Kongsgaard UE, Aasen AO, Smith-Erichsen N., Bjornskau L.: Effects of heparin on proteolytic activities in human plasma. Eur Surg Res24:119-128, 1992
Hirsh J., Levine MN: Low-molecular-weight heparin: Laboratory properties and clinical evaluation. A review. Eur J Surg Suppl 571:9-22, 1994
85.
Young E., Wells P., Holloway S., et al: Ex-vivo and in-vitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost71:300-304,1994
86.
Litin SC, Gastineau DA: Current concepts in anticoagulant therapy. Mayo Clin Proc70:266-272, 1995
87.
Barzu T., van Rijn JL, Petitou M., et al: Heparin degradation in the endothelial cells. Thromb Res47:601-698, 1987
88.
Frydman A.: Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis26:24-38, 1996 (suppl 2)
89.
Ramakrishna R., Manoharan A., Kwan YL, Kyle PW: Heparin-induced thrombocytopenia: Cross-reactivity between standard heparin, low-molecular-weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran). Br J Haematol91:736-738, 1995
90.
Collignon F. , Frydman A., Caplain H., et al: Comparison of the pharmacokinetic profiles of three low-molecular-mass heparins—dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost73:630-640, 1995
91.
Danielsson A. , Raub E., Lindahl U., Bjork I.: Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factorXa. J Biol Chem261:15467-15473, 1986
92.
Bjork I., Lindahl U.: Mechanism of the anticoagulant action of heparin. Mol Cell Biochem48:161-182, 1982
93.
Ofosu FA, Sie P., Modi GJ, et al: The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J243:579-588, 1987
94.
Fareed J., Walenga JM, Hoppensteadt D., et al: Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins [published erratum appears in Haemostasis1988;18(4-6):following 389]. Haemostasis18:3-15, 1988 (suppl 3)
95.
Samama MM, Combe S., Horellou MH, et al: Anti Xa activity and prothrombinase inhibition in patients treated with two different doses of enoxaparin in gynecologic surgery. Thromb Res Suppl 14:29-37, 1991
Massonnet Castel S, Pelissier E., Dreyfus G., et al: Low-molecular-weight heparin in extracorporeal circulation. Lancet1:1182-1183, 1984 (letter)
98.
Massonnet Castel S., Pelissier E., Bara L., et al: Partial reversal of low-molecular-weight heparin (PK 10169) anti-Xa activity by protamine sulfate: In vitro and in vivo study during cardiac surgery with extracorporeal circulation . Haemostasis16:139-146, 1986
99.
Reber G., Schweizer A., de Moerloose P., et al: Comparison between a low-molecular-weight and standard heparin for anticoagulation during extracorporeal CO2 removal in the dog. Thromb Res49:157-168, 1988
100.
Ganjoo AK, Harloff MG, Johnson WD: Cardiopulmonary bypass for heparin-induced thrombocytopenia: Management with a heparin-bonded circuit and enoxaparin. J Thorac Cardiovasc Surg112:1390-1392, 1996
101.
Van Dyck MJ , Lavenne Pardonge E., Azerad MA, et al: Case 5-1996. Thrombosis after the use of a heparin-coated cardiopulmonary bypass circuit in a patient with heparin-induced thrombocytopenia. J Cardiothorac Vasc Anesth10:809-815, 1996
102.
Van Ryn McKenna J., Cai L., Ofosu FA, et al: Neutralization of enoxaparin-induced bleeding by protamine sulfate. Thromb Haemost63:271-274, 1990
103.
Koninger J. , Greinacher A., Muller Beissenhirtz W., Strosche H.: [Heparin-associated thrombocytopenia caused by low-molecular-weight heparin]. Unfallchirurg98:49-51, 1995
104.
Peters FP, Doevendans PA, Erdkamp FL, et al: Low-molecular-weight heparin-induced thrombocytopenia and thrombosis . Eur J Haematol56:329-330, 1996
105.
Slocum MM, Adams JGJr, Teel R., et al: Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg23:839-843, 1996
106.
Gottlieb A. , Tabares AH, Levy P., et al: Use of low-molecular-weight heparin in patients with heparin-induced thrombocytopenia undergoing carotid endarterectomy . Anesthesiology85:678-681, 1996
107.
Gouault-Heilmann M., Huet Y. Contant G., et al: Cardiopulmonary bypass with a low-molecular-weight heparin fraction. Lancet2:1374, 1983 (letter)
108.
Altes A., Martino R., Gari M., et al: Heparin-induced thrombocytopenia and heart operation: Management with tedelparin. Ann Thorac Surg59:508-509, 1995
109.
Robitaille D., Leclerc JR, Laberge R., et al: Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia. J Thorac Cardiovasc Surg103:597-599, 1992
110.
Vun M., Evans S., Chong B.: Cross-reactivity study of low-molecular-weight heparin and heparinoid in heparin-induced thrombocytopenia. Thromb Res81:525-532, 1996
111.
Buchanan MR , Brister SJ, Ofosu F.: Prevention and treatment of thrombosis: Novel strategies arising from our understanding of the healthy endothelium. Wien Klin Wochenschr105:309-313, 1993
112.
Burkhard Meier U, Sohngen D., Schultheiss HP, et al: Heparin-induced thrombocytopenia type II: Successful use of Orgaran (ORG 10172) in intensive care patients. Intensive Care Med21:542-543, 1995 (letter)
113.
Scheffler E., Aulmann M., Remppis A., et al: [Successful use of a heparinoid (danaparoid sodium) for heparin-induced thrombocytopenia type II in aortic valve reoperation] . Z Kardiol84:565-568, 1995
114.
Wilhelm MJ , Schmid C., Kececioglu D., et al: Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172. Ann Thorac Surg61:920-924, 1996
115.
Tardy Poncet B, Mahul P., Beraud AM, et al: Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome . Br J Haematol90:969-970, 1995 (letter)
116.
Danhof M., de Boer A., Magnani HN, Stiekema JC: Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis22:73-84, 1992
117.
Brister SJ , Buchanan MR: Heparinless cardiopulmonary bypass revisited: A newer strategy to avoid heparin-related bleeding using dermatan sulfate . J Cardiothorac Vasc Anesth9:317-321, 1995 (comments)
118.
Gravlee GP : Dermatan sulfate anticoagulation: Future replacement for heparin?J Cardiothorac Vasc Anesth9:237-239, 1995
119.
Fareed J., Hoppensteadt D., Walenga JM, Bick RL: Current trends in the development of anticoagulant and antithrombotic drugs . Med Clin North Am78:713-731, 1994
Griffin LC , Toole JJ, Leung LL: The discovery and characterization of a novel nucleotide-based thrombin inhibitor. Gene137:25-31, 1993
122.
Johnson PH : Hirudin: Clinical potential of a thrombin inhibitor . Ann Rev Med45:165-177, 1994
123.
Katakura S. , Nagahara T., Hara T., Iwamoto M.: A novel factor Xa inhibitor: Structure-activity relationships and selectivity between factor Xa and thrombin. Biochem Biophys Res Commun197:965-972, 1993
124.
Komatsu Y., Misawa S., Sukesada A., et al: CX-397, a novel recombinant hirudin analog having a hybrid sequence of hirudin variants-1 and -3. Biochem Biophys Res Commun196:773-779, 1993
125.
Li WX, Kaplan AV, Grant GW, et al: A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation. Blood83:677-682, 1994
126.
Lidon RM, Theroux P., Lesperance J., et al: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction . Circulation89:1567-1572, 1994
127.
Mesters RM , Heeb MJ, Griffin JH: A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va. Biochemistry32:12656-12663, 1993
128.
Nagahara T. , Yokoyama Y., Inamura K., et al: Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem37:1200-1207, 1994
129.
Neises B., Tarnus C., Broersma RJ, et al: The synthesis and anticoagulant activity of novel peptidylfluoroalkanes . Adv Exp Med Biol340:185-188, 1993
130.
Nishino T. , Nishioka C., Ura H., Nagumo T.: Isolation and partial characterization of a novel amino sugar-containing fucan sulfate from commercial Fucus vesiculosus fucoidan. Carbohydr Res255:213-224, 1994
131.
Oleksyszyn J., Boduszek B., Kam CM, Powers JC: Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases . J Med Chem37:226-231, 1994
132.
Vlasuk GP: Structural and functional characterization of tick anticoagulant peptide (TAP): A potent and selective inhibitor of blood coagulation factor Xa. Thromb Haemost70:212-216, 1993
133.
FitzGerald G.: The human pharmacology of thrombin inhibition . Cor Art Dis7:911-918, 1996
134.
Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation90:1631-1637, 1994
135.
Neuhaus KL , von Essen R., Tebbe U., et al: Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation90:1638-1642, 1994
136.
Chamberlin JR, Lewis B., Leya F., et al: Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol11:511-514, 1995
137.
Lewis BE, laffaldano R., Mckiernan TL, et al: Report of successful use of argatroban as an alternative anticoagulant during coronary stent implantation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Cathet Cardiovasc Diagn38:206-209, 1996
138.
Teasdale SJ , Zulys VJ, Mycyk T., et al: Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis . Ann Thorac Surg48:712-713, 1989
139.
O Yurvati AH, Laub GW, Southgate TJ, McGrath LB: Heparinless cardiopulmonary bypass with ancrod . Ann Thorac Surg57:1656-1658, 1994
140.
Zulys VJ, Teasdale SJ, Michel ER, et al: Ancrod (Arvin) as an alternative to heparin anticoagulation for cardiopulmonary bypass. Anesthesiology71:870-877, 1989
141.
Spiekermann BF, Lake CL, Rich GF, Humphries JE: Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass. Anesthesiology80:686-688, 1994
